Moderna will apply Generation Bio’s proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system to discover and develop non-viral genetic medicines for immune system and liver disorders, through a collaboration that could generate up to $1.876 billion for Generation Bio. Moderna has acquired an option to license both ctLNP and Generation Bio’s closed-end DNA (ceDNA) novel construct technology. The messenger RNA (mRNA)-based vaccine and drug developer plans to use the technologies to produce two novel nucleic acid therapeutics capable of reaching immune cells, as well as two programs designed to treat liver diseases that include rare indications such as Phenylketonuria (PKU) and Wilson disease, as well as more prevalent indications. Moderna also acquired an option for a third program that could target either immune cells or liver disease.
